Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

Video

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 dichloride (Xofigo) and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

The combination of radium-223 and VEGF-targeted agents is feasible and safe. There was no dose limiting toxicity with the combination. There is a particular interest in investigating hematologic toxicity because radium-223 can affect bone marrow, says Bosse.

The toxicity profile is reassuring and overlaps what is known with VEGF targeted therapy, states Bosse. There was only one event of grade 3 anemia, which was not unexpected in the RCC population.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.